Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel
Roger D. Dansey net worth and biography

Roger Dansey Biography and Net Worth

Insider of Seagen
Roger joined Seagen as Chief Medical Officer in 2018, bringing extensive experience in cancer drug development. His deep oncology background and proven leadership has helped Seagen evolve into a global, multi-product oncology company.

Previously, Roger was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda® (pembrolizumab) across multiple tumor types. Earlier in his career, Roger was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva® (denosumab) at Amgen, where he held multiple roles in oncology and hematology.

Roger holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa. He serves as a member of the board of directors for INOVIO Pharmaceuticals, Inc.

What is Roger D. Dansey's net worth?

The estimated net worth of Roger D. Dansey is at least $11.94 million as of October 17th, 2022. Dr. Dansey owns 97,539 shares of Seagen stock worth more than $11,939,749 as of December 3rd. This net worth estimate does not reflect any other assets that Dr. Dansey may own. Additionally, Dr. Dansey receives an annual salary of $1,530,000.00 as Insider at Seagen. Learn More about Roger D. Dansey's net worth.

How old is Roger D. Dansey?

Dr. Dansey is currently 66 years old. There are 5 older executives and no younger executives at Seagen. Learn More on Roger D. Dansey's age.

What is Roger D. Dansey's salary?

As the Insider of Seagen Inc., Dr. Dansey earned a total compensation package of $8,861,140.00 in 2021. Dr. Dansey earned a salary of $754,614.00, stock awards of $4,640,041.00, options awards of $2,692,014.00, non-equity compensation of $756,325.00, and other compensation of $18,146.00. Learn More on Roger D. Dansey's salary.

How do I contact Roger D. Dansey?

The corporate mailing address for Dr. Dansey and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected] Learn More on Roger D. Dansey's contact information.

Has Roger D. Dansey been buying or selling shares of Seagen?

Roger D. Dansey has not been actively trading shares of Seagen within the last three months. Learn More on Roger D. Dansey's trading history.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Are insiders buying or selling shares of Seagen?

In the last twelve months, insiders at the biotechnology company sold shares 32 times. They sold a total of 258,784 shares worth more than $37,994,185.43. The most recent insider tranaction occured on November, 17th when insider Jean I Liu sold 8,333 shares worth more than $1,092,039.65. Insiders at Seagen own 27.3 % of the company. Learn More about insider trades at Seagen.

Information on this page was last updated on 11/17/2022.

Roger D. Dansey Insider Trading History at Seagen

See Full Table

Roger D. Dansey Buying and Selling Activity at Seagen

This chart shows Roger D. Dansey's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $122.41
Low: $120.12
High: $122.84

50 Day Range

MA: $130.29
Low: $117.37
High: $139.17

2 Week Range

Now: $122.41
Low: $105.43
High: $183.00

Volume

723,087 shs

Average Volume

1,140,982 shs

Market Capitalization

$22.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58
Our Top 5 Microcap Stocks
Microcap stocks tend to be an under-researched area… Which increases the odds of discovering attractive investment opportunities.

Just like these 5 which appear to be in an excellent position to see a surge in share price.
>>> See All 5 Here
pixel